Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 20, 2026.

Hypoxia and Inflammation: Insights From High-Altitude Physiology

Kathy Pham, Keval Parikh, Erica C. Heinrich

Frontiers in Physiology · 2021 · Review · CC BY

doi:10.3389/fphys.2021.676782

Abstract

The key regulators of the transcriptional response to hypoxia and inflammation (hypoxia inducible factor, HIF, and nuclear factor-kappa B, NF-κB, respectively) are evolutionarily conserved and share significant crosstalk. Tissues often experience hypoxia and inflammation concurrently at the site of infection or injury due to fluid retention and immune cell recruitment that ultimately reduces the rate of oxygen delivery to tissues. Inflammation can induce activity of HIF-pathway genes, and hypoxia may modulate inflammatory signaling. While it is clear that these molecular pathways function in concert, the physiological consequences of hypoxia-induced inflammation and how hypoxia modulates inflammatory signaling and immune function are not well established. In this review, we summarize known mechanisms of HIF and NF-κB crosstalk and highlight the physiological consequences that can arise from maladaptive hypoxia-induced inflammation. Finally, we discuss what can be learned about adaptive regulation of inflammation under chronic hypoxia by examining adaptive and maladaptive inflammatory phenotypes observed in human populations at high altitude. We aim to provide insight into the time domains of hypoxia-induced inflammation and highlight the importance of hypoxia-induced inflammatory sensitization in immune function, pathologies, and environmental adaptation.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 20, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Inflammation plays a key role in the physiological response to hypoxic stress. Tissues experience hypoxia during injury, infection, hypoperfusion, ischemia, or hypoxemia secondary to sleep apnea, pulmonary disease, anemia, high-altitude exposure, or other causes. Cellular hypoxia can trigger the expression of several inflammatory mediators which signal tissue damage and initiate survival responses. However, while hypoxia-induced inflammation may serve a protective role by initiating an immune response and promoting tissue healing, it can also contribute to several pathologies, particularly in the context of chronic hypoxia. In this review, we summarize the known crosstalk between the transcriptional responses to hypoxia and inflammation and highlight the physiological consequences that occur as a result of maladaptive hypoxia-induced inflammation. Finally, we review what we know about adaptive regulation of inflammation under chronic hypoxia by investigating inflammatory phenotypes in human populations adapted to high altitude.

Hypoxia-Inducible Factor Pathway

The transcriptional response to hypoxia is controlled by the hypoxia-inducible factor (HIF) signaling cascade. HIF is a heterodimer protein composed of an oxygen-sensitive alpha subunit and constitutively expressed beta subunit. The three HIF isoforms (HIF-1, HIF-2, and HIF-3) have some overlapping roles but also demonstrate distinct functions in different cell types. Under normoxic conditions, HIF-α is hydroxylated by oxygen-dependent prolyl hydroxylases (PHDs 1–3 in humans; Figure 1). Upon hydroxylation, HIF-α is ubiquitinated by the von Hippel-Lindau tumor suppressor protein (pVHL) and degraded by proteasomes. Since PHD requires oxygen as a co-substrate, its activity decreases under hypoxic conditions, allowing HIF-α to dimerize with HIF-β and translocate to the nucleus. The HIF complex can then bind to hypoxia response elements (5'-RCGTG-3') in gene promoters to regulate expression of at least 100 genes to coordinate increased oxygen supply to hypoxic tissue. HIF pathway activity is associated with activation of genes involved in metabolic adaptation, such as phosphoglycerate kinase (PGK) and lactate dehydrogenase A (LDHA), vascularization via vascular endothelial growth factor (VEGF), as well as red blood cell production via erythropoietin (EPO), and several other genes involved in improving oxygen delivery and use efficiency.

HIF and NF-κB Crosstalk

While the HIF pathway primarily responds to hypoxia, HIF expression is also increased in response to non-hypoxic stimuli, including bacterial lipopolysaccharide (LPS), tumor necrosis factor-α (TNF-α), reactive oxygen species, hepatocyte growth factor, and interleukin (IL)-18 via crosstalk with the nuclear factor-κB (NF-κB) pathway. The NF-κB transcription factor is a master regulator of inflammation. NF-κB is kept localized in the cytoplasm by inhibitory IκB proteins, which thereby inhibit DNA binding by NF-κB. In response to inflammatory stimuli and microbial products, the IκB kinase (IKK) complex phosphorylates IκB, leading to IκB ubiquitination and proteasomal degradation. With the degradation of IκB, NF-κB can translocate to the nucleus and upregulate key downstream inflammatory pathways (;;; Figure 1).

The NF-κB pathway can also upregulate HIF-1α. NF-κB subunits bind to the NF-κB binding element within the HIF-1α gene promoter region and induce HIF-1α mRNA expression. Several studies support this NF-κB-dependent HIF-1α expression. For example, in cell culture models (HEK293 cells and pulmonary artery smooth muscle cells); NF-κB transfection resulted in increased HIF-1α mRNA and protein expression. Additionally, when these cells were co-transfected with a mutated dominant negative IκB (which cannot be phosphorylated by IKK) to reduce NF-κB translocation to the nucleus, HIF-1α mRNA and protein expression decreased.

In addition to this direct link, the HIF and NF-κB pathways also share common regulators. Like HIF-α, the IKK complex responsible for regulating NF-κB activity is also a target of PHD and therefore its NF-κB regulatory activity is oxygen dependent. In normoxic conditions, PHD hydroxylates IKKβ, therefore repressing NF-κB nuclear translocation and transcriptional activity. When PHD is rendered inactive in hypoxic conditions, the IKK complex can proceed to remove IκB from NF-κB, increasing its rate of translocation to the nucleus and upregulating inflammatory gene expression (Figure 1;; ).

Hypoxia-Induced Inflammation: Adaptive or Maladaptive?

At short timescales, and at the tissue level, inflammatory signaling in response to hypoxia is an adaptive mechanism which evolved to promote cell survival during infection, injury, or oxygen limitation. However, chronic and/or systemic hypoxia can produce maladaptive inflammation which can contribute to disease development. For example, in a clinical context, the crosstalk between hypoxia and inflammation may contribute to several inflammation-mediated metabolic and cardiovascular comorbidities that accompany hypoxia-promoted diseases such as chronic obstructive pulmonary disease or obstructive sleep apnea. This can also be investigated in the context of high-altitude exposure, where inflammatory signaling pathways and immune function must respond and adapt to acute, chronic, or lifelong hypoxemia. Here, we will examine our current understanding of how the interaction between hypoxia and inflammation contributes to high-altitude illness and what we might learn about the adaptive regulation of hypoxia-induced inflammation from high-altitude native populations (Figure 2).

The Role of Inflammation in High-Altitude Illness

High-altitude illnesses are a common risk for sojourners to high altitude (>2,500 m elevation). Within the first week of exposure, sojourners often present with Acute Mountain Sickness (AMS), which is characterized by headache, nausea, fatigue, and gastrointestinal issues. AMS typically resolves with acclimatization. However, in serious cases, sojourners may develop severe and potentially fatal illnesses, such as high-altitude pulmonary edema (HAPE), high-altitude pulmonary hypertension (HAPH), or high-altitude cerebral edema (HACE;;; ). The incidence and severity of HAPH, HAPE and HACE vary depending on multiple factors, such as ascent time, altitude, and timely recognition and treatment. Despite several decades of examining the physiology of AMS, HAPH, HAPE, and HACE, some questions remain regarding the pathophysiology of these conditions and the extent to which inflammation contributes to their onset and progression.

Acute Mountain Sickness

AMS development results from a complex network of physiological responses to hypoxia (i.e., inflammation, vasogenic edema, and acidosis) as well as anatomical factors (i.e., insufficient cerebrospinal fluid production, varied cerebral venous blood flow;; ). While there is substantial research on potential contributors to AMS (reviewed in; ), the exact biological pathways and molecular mechanisms behind AMS development remain unclear.

Recent studies support a potential role of inflammation in AMS. There is a general consensus that pro-inflammatory cytokines and other inflammatory markers (most notably C-Reactive protein (CRP), IL-1β, and IL-6) are increased in individuals acutely exposed to hypoxia or high altitude. In some cases, inflammatory mediator expression appears to differ across individuals who develop AMS and those who do not. For example, individuals who develop AMS have been reported to show decreased plasma levels of IL-10 and increased IL-1β, IL-6, and TNF-α compared to non-AMS controls. Furthermore, the association between plasma IL-6 and AMS score has been identified by multiple independent groups.

While these studies indicate that some circulating pro-inflammatory markers may be associated with AMS development, it is not yet clear what specific role they may play. It is possible that hypoxia initiates the release of inflammatory and angiogenic mediators which disrupt the blood-brain barrier and promote vasogenic edema. A complementary hypothesis is that protection from AMS may be driven by a robust anti-inflammatory response which protects against potential increased blood-brain barrier permeability caused by acute systemic inflammation. This is supported by data from, who found higher levels of anti-inflammatory marker (IL-1RA, HSP70, and adrenomedullin) expression in AMS-resistant compared to AMS-susceptible individuals.

Finally, both steroids and nonsteroidal anti-inflammatory drugs (NSAIDS) equally reduce AMS incidence despite their different modes of action. This suggests that both COX-2 mediated inflammation as well as analgesic mechanisms that mediate nociception contribute to AMS symptomology. Indeed, inflammatory mediators released during tissue injury can activate nociceptors and can contribute to pain hypersensitivity. However, note no change in AMS symptoms in individuals receiving Ibuprofen at normal recommended doses of 400mg three times a day, perhaps, due to the lower dosage compared to other studies which did observe a reduction in AMS symptoms with a higher Ibuprofen dose (600 mg three times a day;,; ).

High Altitude Cerebral Edema

HACE is a severe and potentially fatal complication that can occur in individuals who travel above 2000 m. HACE is accompanied by symptoms including headache, ataxia, declines in cognitive function, and can lead to seizures. As with AMS, HACE is most common with rapid ascent. HACE is frequently preceded by some AMS symptoms, and both illnesses are influenced by cerebral hemodynamics. As a result, HACE is sometimes considered a more severe form of AMS, however, additional distinct pathophysiological mechanisms contribute to HACE development. HACE can develop spontaneously at very high altitudes in acclimatized individuals. HACE appears to occur as a result of hypoxia-mediated cerebral vasodilation and a subsequent impairment of the autoregulation of cerebral blood flow, loss of blood-brain barrier integrity, and a rise in intracranial pressure. Ultimately, cytotoxic and vasogenic edema leads to microvascular disruption and microbleeds.

While some aspects of HACE pathophysiology remain uncertain, the underlying mechanisms producing HACE are likely similar to those of AMS and inflammation may play a role in its development. In both mouse and rat models, pro-inflammatory cytokines are significantly increased in the brain cortex after hypoxia exposure. Furthermore, when pre-treated with bacterial LPS to produce a systemic inflammatory response, subsequent hypoxia exposure results in cerebral edema. It is proposed that pre-existing inflammation increases aquaporin 4 (AQP4) activity in astrocytes via toll-like receptor 4 (TLR4), mitogen-activated protein kinase (MAPK), and NF-κB signaling, thereby increasing astrocyte permeability. Together, these data indicate that when challenged with a combination of hypoxia and inflammation, the combination of increased pro-inflammatory cytokines and increased blood vessel permeability produces vasogenic edema.

Although this data provide intriguing support for a role of hypoxia-induced inflammation and HIF-NF-kB crosstalk in HACE onset, it remains unclear if inflammation is a proximal cause of AMS or HACE. Nonetheless, inflammation likely plays a contributing role in susceptibility and progression of these illnesses. Further work is required to reach a unified explanation for HACE development.

High-Altitude Pulmonary Hypertension and High-Altitude Pulmonary Edema

HAPH occurs due to general hypoxic pulmonary vasoconstriction (HPV). Under typical conditions, local HPV aids in redistributing blood flow away from lung regions with poor ventilation and improves pulmonary gas exchange. However, at high altitude, global reductions in alveolar oxygen pressure can lead to HPV throughout the lung and increase mean pulmonary artery pressures. HAPH is estimated to impact up to 10% of high-altitude residents. The clinical presentation of HAPH includes dyspnea, general fatigue, exercise intolerance, and in severe cases, chest pain and mental alterations, and ultimately cor pulmonale.

While acute HAPH is primarily driven by increased vasomotor tone, chronic hypoxic stress and persistent pulmonary hypertension can produce vascular remodeling and exacerbate pulmonary artery pressures. The hallmark of vascular remodeling in chronic hypoxia is increased vessel muscularization. It is predicted that inflammation plays an important role in this remodeling process. Chronic hypoxia produces a proinflammatory microenvironment in pulmonary artery walls. Resident fibroblasts, immune cells, and progenitor cells in the vascular adventitia respond to this local cellular stress by releasing additional inflammatory mediators and growth factors which impact vascular wall cell phenotypes and contribute to increased muscularization. This inflammatory microenvironment also promotes recruitment, retention, and differentiation of additional inflammatory cells.

HAPE occurs most commonly during rapid ascent. This is due to exaggerated HPV which causes acute pulmonary hypertension, increased capillary permeability, and alveolar fluid buildup. HAPE onset is primarily due to this non-inflammatory hydrostatic pulmonary edema. However, inflammation may play a downstream role in HAPE pathology. Several studies report increased inflammatory mediators and chemokines in bronchoalveolar fluid in later stages of the illness including leukotriene B4 and complement fragments (C5a;, ), plasma endothelin-1 (ET-1; ), lactate dehydrogenase, IL-1β, IL-6, IL-8, TNF-α, and IL-1RA. Several of these studies also report increased leukocyte counts in bronchoalveolar lavage fluid. This late-stage inflammation could exacerbate pulmonary vascular leakage by causing endothelial damage and increasing capillary permeability.

Some studies have also suggested that inflammation contributes to HAPE susceptibility. Individuals with a history of HAPE are more susceptible to developing HAPE again upon re-entry to high altitude. This increased susceptibility is attributed to higher baseline inflammation. Furthermore, one report suggests that HAPE-susceptible individuals also demonstrate reduced lung function compared to HAPE-resistant individuals, which would limit the adaptive compensatory ventilatory response to hypoxia. The reduced lung function in these individuals is further correlated with increased plasma CRP. This association between chronic inflammation and poor lung function is hypothesized to contribute to HAPE-susceptibility, although it does not explain the direct cause of onset. Additionally, pre-existing pulmonary vascular remodeling, driven partially by inflammation, may exacerbate pulmonary pressures and blood flow distribution and thereby increase HAPE susceptibility.

Inflammation and Erythropoiesis

Erythropoiesis is tightly regulated to maintain homeostatic balance between red blood cell production and degradation. This balance is crucial for optimal oxygen delivery to tissues. An inadequate number of erythrocytes lead to tissue hypoxia, while high erythrocyte concentrations can increase blood viscosity, impair blood flow, and increase risk of thrombosis. This is particularly relevant in Chronic Mountain Sickness (CMS), a clinical syndrome commonly presented in high-altitude natives and life-long residents, which frequently coincides with excessive erythrocytosis (Hb ≥ 19 g/dL for women, Hb ≥ 21 g/dL for men) in some high altitude groups. The HIF pathway plays a key role in regulating erythropoiesis. HIF activation results in increased transcription of the EPO gene in the kidney and liver, and EPO serum concentration can increase up to several 100-fold in response. Additionally, HIF activity plays a role in regulating iron uptake from the gut and mobilizing erythroid progenitor cells in the bone marrow.

Chronic inflammation typically leads to anemia through several mechanisms: prioritizing myeloid cell production, sequestering iron, and increasing erythroid turnover rate. Inflammation impacts crucial sites of erythrocyte production to redistribute resources toward myeloid cell production and therefore reduces lymphoid and erythroid output. For example, expression of pro-inflammatory IL-1β, interferon gamma (IFNγ), and IL-6 skew multipotential hematopoietic progenitors toward myeloid cell development. This is an adaptive response since myeloid cells are needed to fight infection; however, this comes at the cost of bone marrow erythropoiesis. Additionally, while iron is an essential component of hemoglobin synthesis, it is also an essential micronutrient to pathogens. During inflammation, increased IL-6 induces hepcidin production, interrupting iron absorption from the gut and blocking iron release from macrophages, leading to hypoferremia. By decreasing iron availability, the immune system limits pathogen proliferation; however, a consequence of iron sequestration is that this also limits iron availability for red blood cell production.

When steady state erythropoiesis becomes insufficient, or red blood cells are broken down at high rates, a compensatory extramedullary mechanism called stress erythropoiesis is initiated to prevent lethal anemia. Stress erythrocytosis produces a burst of new erythrocytes to maintain red cell concentrations until bone marrow erythropoiesis recovers. The mechanism of stress erythropoiesis has been studied extensively in mice, where it occurs in the spleen and liver in response to anemia, hypoxia, or sterile inflammation. Studies in mice revealed that sterile inflammation produced by phenylhydrazine injections lead to decreased erythroid progenitor cells in the bone marrow and increased erythroid progenitor cells in the spleen. It was discovered that bone marrow erythroid progenitor cells and splenic erythroid progenitor cells respond to different factors, indicating that splenic progenitors are distinct from bone marrow progenitors. This splenic stress erythropoiesis response depends on TLR signaling molecules Myd88 and TRIF. Furthermore, pro-inflammatory cytokines TNF-α and IL-1β promote the expansion of splenic erythroid progenitors. It is currently unknown if similar mechanisms are responsible for stress erythropoiesis in humans. Future studies may investigate biomarkers of stress erythropoiesis signaling to determine if this protective mechanism is active during high-altitude exposure or other forms of hypoxic stress.

Impacts of Chronic Hypoxia on Immune Function and Inflammatory Signaling

Immune cells are exposed to hypoxia when they are recruited to sites of inflammation. In physiological immunological niches (bone marrow, placenta, gastrointestinal tract mucosal surfaces, and lymph nodes), the maintenance of sustained and moderate physiological hypoxia is an adaptive mechanism to regulate metabolic pathways and immune homeostasis. However, in pathological immunological niches (tumors and chronically inflamed and ischemic tissue), severe and unregulated hypoxia can lead to maladaptive inflammation and disease development. In either case, the immune cell response to hypoxia hinges upon the ability to mount a transcriptional response. Therefore, HIF activity is essential to immune cell survival and function.

Several studies demonstrate the significance of HIF signaling in immune function. HIF-1α deletion in myeloid cells (granulocytes and monocytes/macrophages) impairs their mobility, aggregation, antibacterial activity, and survival. On an organismal level, HIF-1α deletion in macrophages can reduce mortality in LPS-induced sepsis in mice. HIF-2α can also directly regulate pro-inflammatory cytokine expression in myeloid cells. In addition to HIF’s essential role in immune cell function, NF-kB is also critical to cell survival in hypoxia. demonstrated that the transcription of the NF-κB p65 subunit is regulated by hypoxia. Neutrophils cultured in hypoxia and treated with NF-κB inhibitors had reduced survival rates, suggesting that activation of the NF-κB pathway promotes neutrophil survival in hypoxia.

Despite this important interplay between hypoxia and inflammation in immune function, we know little about how inflammatory signaling and immune function adapt to chronic sustained or chronic intermittent hypoxia. Studies in animal models demonstrate potential blunting or sensitization of inflammatory responses to infection as a result of chronic hypoxia exposure. A study in salmon exposed to chronic hypoxia for 58 days found blunted expression of pro-inflammatory genes in macrophages and the head kidney in response to a viral inflammatory stimulus. Alternatively, in a mouse model, 36 days of hypoxia exposure lead to an enhanced immunological response to LPS illustrated by higher antibody titers and higher TNF-α expression, indicating that hypoxia may stimulate innate and adaptive immune responses.

Among studies in humans, chronic hypoxia also appears to modulate immune function and inflammatory signaling. A study of women exposed to high altitude (5,050 m) for 21 days showed increased white blood cells, reductions in CD3+ and CD4+ T-cells, an increase in natural killer cells, and a decrease in IFNγ expression by circulating T-cells. Another recent study in humans exposed to high altitude (3,232 m) for up to 11 months shows that cytokine expression in response to inflammatory stimuli were also higher than sea-level values. The possibility that chronic hypoxia exposure in humans leads to immune sensitization and hypersensitivity to inflammatory stimuli warrants future study. Since several critical and chronic illnesses are associated with hypoxemia (e.g., sepsis, acute respiratory distress syndrome, chronic obstructive pulmonary disease, and sleep apnea), it is possible that inflammatory dysregulation in these conditions may be caused in part by this concurrent hypoxic stress.

Lessons From High-Altitude Acclimatized and Adapted Groups

High altitude environments are physiologically stressful due to low atmospheric pressure and oxygen limitation. Despite this, humans have survived in these environments for thousands of years and different high-altitude native populations exhibit distinct physiological adaptations that may be associated with genetic variants. In this section, we discuss what can be learned from high-altitude acclimatized and adapted populations about how inflammatory pathways respond to chronic hypoxia.

Inflammatory Pathway Genes Under Selection in High-Altitude Groups

Several studies have identified genes under evolutionary selection in high-altitude native populations. HIF pathway genes, particularly EGLN1 and EPAS1, are consistently highlighted across studies. Additionally, several genes associated with inflammation also show signals of selection but have received less attention. The inflammatory pathway genes IL6, IL1A, IL1B, NOS1, NOS2, and TNF show signals of evolutionary selection in both Andean and Tibetan high-altitude native populations. NOS1 and NOS3 have also been shown to be under positive selection in the Sherpa population. Additional inflammation-related genes have been reported to be under selection in individual groups, including HLA-DQB1, PPARA, and TGFBR3 in Tibetans, PPARA in Sherpas, BRINP3, DUOX2, and CLC in Andeans, and AIMP1 in Ethiopians. Table 1 summarizes inflammation-related genes found to be under evolutionary selection in high altitude human populations.

IL6 is particularly interesting given that its expression has been associated with AMS development. IL-6 is also noted to increase hematopoietic stem cell proliferation under hypoxic conditions, and its effects on red cell production are synergistic with other pro-inflammatory cytokines, including IL-1α and TNF-α. Together, this data suggest that IL-6 plays a role in adaptation to chronic hypoxia. It is currently unknown what the precise adaptive IL6 variants are, but it is possible that blunting IL-6 expression in response to chronic hypoxia or chronic intermittent hypoxia may provide an advantage by preventing hypoxia-induced chronic low-grade systemic inflammation. Another important inflammatory gene under selection in both Tibetan and Andean groups is TNF, a multifunctional pro-inflammatory cytokine. TNF-α levels have also been found to be elevated in individuals traveling acutely to high altitude. Like IL6, the adaptive TNF variant is unknown but modulation of TNF expression in response to chronic hypoxia may be important for preventing chronic inflammation at high altitude.

In addition to these genetic changes, epigenetic mechanisms also play a critical role in regulating expression of inflammatory genes and likely influence adaptation of inflammatory pathways to chronic hypoxia. Epigenetic changes alter gene expression without altering the underlying genetic code. These changes include DNA methylation, histone modifications, and microRNA expression. These epigenetic changes play key roles in environmental adaptation during development and exposure in adulthood. There are several HIF-dependent and independent mechanisms by which hypoxia significantly impacts epigenetic modifications. For example, HIF induces expression of several histone methyltransferases and demethylases. Additionally, hydroxylation of histone methyl transferases as well as activity of histone demethylases, are oxygen dependent. DNA methylation patterns are also altered by hypoxia, in part due to the impact on ten-eleven translocation (TET) enzyme expression and activity. The HIF consensus binding site also contains a CpG dinucleotide, indicating that expression of HIF-pathway genes may be dependent on DNA methylation. Given that immune cell phenotypes, including inflammatory macrophage phenotypes, can be regulated by epigenetic modifications, hypoxia has the potential to significantly alter immune cell function via its impact on epigenetics. These changes may occur within or across generations of exposure. Future work should investigate if high-altitude acclimatized or adapted groups develop particular patterns of DNA methylation or histone modification, which protect against chronic hypoxia-induced inflammation. Over generations, mutations at loci containing CpG sites could also assist in blunting inflammatory gene expression in the face of chronic hypoxic stress.

Nitric Oxide in Native and Acclimatized High-Altitude Groups

Nitric oxide (NO) is a natural vasodilator that plays a crucial role in regulating vasodilation in vascular smooth muscle. Exhaled NO is also used as marker of airway inflammation. The vasodilatory function of NO protects against pulmonary hypertension at high altitude. Individuals exposed acutely to high altitude tend to show reduced gas phase NO, which typically returns to baseline levels after a couple days then exceeds baseline levels by 5 days. However, gas phase NO has been demonstrated to remain low in HAPE-sensitive individuals, perhaps, indicating that deficits in pulmonary epithelial NO synthesis contribute to exaggerated pulmonary vasoconstriction and edema. Tibetan and Bolivian high-altitude adapted populations also show elevated exhaled NO compared to sea-level residents. This phenotype correlates with higher pulmonary blood flow and protection from HAPH. However, demonstrate that enhanced NO production may not be unique to high-altitude native populations since individuals of Han Chinese ancestry living at high altitude (3,660–3,700 m) demonstrated an even higher average NO metabolite production than Tibetans at the same altitude. Another study reports that the native Sherpa population has a lower level of circulating NO in serum and no differences in circulating NO metabolites in comparison to low-altitude samples. Interestingly, this finding contrasts the high exhaled NO among Tibetans. This discrepancy in NO substrate bioavailability in Tibetans vs. Sherpas also suggests that these two high-altitude populations may have some distinct adaptation in the nitric oxide pathway.

Elevated NO may also be an important adaptation of the immune system to chronic hypoxia-induced inflammation. Under normal physiological conditions, NO plays an anti-inflammatory role and inhibits platelet aggregation and rolling, adherence, and transmigration of leukocytes. During inflammatory reactions, the production of the inducible form of nitric oxide synthase in many immune cells, including monocytes, macrophages, and neutrophils leads to very large increases in NO by up to 1,000-fold. NO can then become oxidized to reactive nitrogen oxide species which nitrosate thiol groups in glutathione. This inhibits the activity of many proteins including mitochondrial enzymes and transcription factors. As a result, elevated NO production can impair pathogen function. At high concentrations, NO also stabilizes HIF by inhibiting HIF PHDs. Therefore, NO production during periods of inflammation permit increased expression of HIF-pathway genes as a protective mechanism since tissue inflammation often leads to cellular hypoxia. However, demonstrated in a rat model that while there is an increase in endothelial nitric oxide synthase (eNOS; NOS3) in chronic hypoxia and chronic intermittent hypoxia conditions, NO bioavailability may be impaired due to increases in asymmetric dimethylarginine (ADMA), a competitive nitric oxide synthase inhibitor that regulates NO production, and hypoxia-induced increase in oxidative stress. ADMA displaces L-arginine, a NOS substrate, and therefore an increase in ADMA concentrations may result in lower NO substrate bioavailability. Oxidative stress may lead to superoxide radical production, which may mediate NO degradation and attenuate NO bioavailability.

Since both NOS1 (nitric oxide synthase 1, neuronal) and NOS2 (nitric oxide synthase 2, inducible) are under selection in multiple high-altitude groups, it is clear that adjusting NO production is a key adaptive phenotype for life at high altitude. While the precise adaptive mechanism is unknown, it likely involves protection against pulmonary hypertension and/or modulation of hypoxia-induced inflammation.

Carbon Monoxide in Adapted High-Altitude Groups

Carbon monoxide (CO) is emerging as a potential therapeutic target for inflammatory modulation due to its anti-inflammatory, anti-apoptotic, and anti-proliferative effects. CO is also used as a clinical marker for inflammation and red blood cell turnover since endogenous CO is only produced through the heme oxygenase (HO) pathway. HO is responsible for catabolizing free heme proteins into Fe2+, CO, and biliverdin. These end products provide cytoprotective benefits and protect cells from programmed cell death in response to pro-inflammatory agonists. The HO-CO pathway may be a key regulator of hypoxia-induced inflammation since the gene encoding heme oxygenase-1 (HMOX1) is upregulated in response to HIF-pathway activation and HO-1 can inhibit NF-κB.

High altitude exposure has been shown to increased exhaled CO levels, and carboxyhemoglobin levels are positively associated with hematocrit in Andean high-altitude residents. This is suspected to be caused by increased red blood cell turnover, a persistent stress erythropoiesis response, or a unique HO/CO pathway mechanism. Interestingly, the gene encoding the constitutively expressed heme oxygenase-2 (HMOX2) is under evolutionary selection in Tibetan high-altitude native groups. The adaptive HMOX2 variants in Tibetans are predicted to play a critical role in regulating red blood cell turnover and potentially contribute to the low hemoglobin concentrations in this group by increasing heme oxygenase activity. Due to the key role that the HO-CO pathway plays in linking the molecular responses to hypoxia and inflammation, as well as evidence that HO is a top candidate for evolutionary selection in high-altitude populations, future research should continue to investigate potential therapeutic uses of exogenous CO and HO pathway activation for modulating inflammatory responses, especially in hypoxia-promoted pathologies.

Conclusion

HIF-NF-κB crosstalk plays an essential role in the transcriptional response to both hypoxia and inflammation. However, additional research is necessary to understand the physiological implications of these pathway interactions at an organismal level. Several studies have demonstrated that select inflammatory mediators are upregulated at high altitude, or in the presence of acute hypoxia, even in the absence of infection. Since these studies have focused on candidate inflammatory markers, large scale transcriptomic or proteomic studies would provide a better understanding of how inflammatory networks are shifted during chronic hypoxia. Further, our understanding of the time domains of hypoxia-induced inflammation and the impact on immune function may also provide insight into pathology of high-altitude illnesses and highlight the importance of hypoxia-induced inflammatory sensitization in critical and chronic illnesses including chronic obstructive pulmonary disorder, sepsis, and COVID-19. This work may identify novel therapeutic targets for mitigating excessive inflammation in patients with concomitant hypoxemia and systemic inflammation.

Author Contributions

KaP drafted versions of the manuscript with input and revisions from KeP and EH. All authors contributed to the article and approved the submitted version.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 164

  1. 1.

    Arias-Stella J. Saldana M. (1963 ). The terminal portion of the pulmonary arterial tree in people native to high altitudes. Circulation 28, 915–925., PMID:

    Not in our library10.1161/01.cir.28.5.915

  2. 2.

    Bailey D. M. Bärtsch P. Knauth M. Baumgartner R. W. (2009 ). Emerging concepts in acute mountain sickness and high-altitude cerebral edema: From the molecular to the morphological. Cell. Mol. Life Sci. 66, 3583–3594., PMID:

    Not in our library10.1007/s00018-009-0145-9

  3. 3.

    Bärtsch P. (1999 ). High altitude pulmonary edema. Med. Sci. Sports Exerc. 31, 23–27.

    Not in our library10.1097/00005768-199901001-00004

  4. 4.

    Batie M. Frost J. Frost M. Wilson J. W. Schofield P. Rocha S. (2019 ). Hypoxia induces rapid changes to histone methylation and reprograms chromatin. Science 363, 1222–1226., PMID:

    Not in our library10.1126/science.aau5870

  5. 5.

    Bayarsaihan D. (2011 ). Epigenetic mechanisms in inflammation. J. Dent. Res. 90, 9–17., PMID:

    Not in our library10.1177/0022034510378683

  6. 6.

    Baze M. M. Hunter K. Hayes J. P. (2011 ). Chronic hypoxia stimulates an enhanced response to immune challenge without evidence of an energetic tradeoff. J. Exp. Biol. 214, 3255–3268., PMID:

    Not in our library10.1242/jeb.054544

  7. 7.

    Beall C. (2007 ). Two routes to functional adaptation: Tibetan and Andean high-altitude natives. Proc. Natl. Acad. Sci. U. S. A. 104, 8655–8660., PMID:

    Not in our library10.1073/pnas.0701985104

  8. 8.

    Beall C. M. Laskowski D. Erzurum S. C. (2012 ). Nitric oxide in adaptation to altitude. Free Radic. Biol. Med. 52, 1123–1134., PMID:

    Not in our library10.1016/j.freeradbiomed.2011.12.028

  9. 9.

    Beall C. M. Laskowski D. Strohl K. P. Soria R. Villena M. Vargas E.. (2001 ). Pulmonary nitric oxide in mountain dwellers. Nature 414, 411–412., PMID:

    Not in our library10.1038/35106641

  10. 10.

    Beg A. A. Jr A. S. B. (1993 ). The IKB proteins: multifunctional regulators of Rel/NF-KB transcription factors. Genes Dev. 7, 2064–2070., PMID:

    Not in our library10.1101/gad.7.11.2064

  11. 11.

    BelAiba R. S. Bonello S. Zähringer C. Schmidt S. Hess J. Kietzmann T.. (2007 ). Hypoxia up-regulates hypoxia-inducible factor-1α transcription by involving phosphatidylinositol 3-kinase and nuclear factor κB in pulmonary artery smooth muscle cells. Mol. Biol. Cell 18, 4691–4697., PMID:

    Not in our library10.1091/mbc.e07-04-0391

  12. 12.

    Bennett L. F. Liao C. Quickel M. D. Yeoh B. S. Vijay-Kumar M. Hankey-Giblin P.. (2019 ). Inflammation induces stress erythropoiesis through heme-dependent activation of SPI-C. Sci. Signal. 12, 1–14., PMID:

    Not in our library10.1126/scisignal.aap7336

  13. 13.
    The role of hypoxia in inflammatory disease (Review) · 2015
    No notice
  14. 14.
    Identifying Signatures of Natural Selection in Tibetan and Andean Populations Using Dense Genome Scan Data · 2010
    No notice
  15. 15.

    Bigham A. W. Lee F. S. (2014 ). Human high-altitude adaptation: forward genetics meets the HIF pathway. Genes Dev. 28, 2189–2204., PMID:

    Not in our library10.1101/gad.250167.114

  16. 16.

    Birrell M. A. McCluskie K. Hardaker E. Knowles R. Belvisi M. G. (2006 ). Utility of exhaled nitric oxide as a noninvasive biomarker of lung inflammation in a disease model. Eur. Respir. J. 28, 1236–1244., PMID:

    Not in our library10.1183/09031936.00048506

  17. 17.

    Bogdan C. (2001 ). Nitric oxide and the immune response. Nat. Immunol. 2, 907–916., PMID:

    Not in our library10.1038/ni1001-907

  18. 18.

    Bonello S. Zähringer C. BelAiba R. S. Djordjevic T. Hess J. Michiels C.. (2007 ). Reactive oxygen species activate the HIF-1α promoter via a functional NFκB site. Arterioscler. Thromb. Vasc. Biol. 27, 755–761., PMID:

    Not in our library10.1161/01.atv.0000258979.92828.bc

  19. 19.

    Boos C. J. Woods D. R. Varias A. Biscocho S. Heseltine P. Mellor A. J. (2016 ). High altitude and acute mountain sickness and changes in circulating endothelin-1, interleukin-6, and interleukin-17a. High Alt. Med. Biol. 17, 25–31., PMID:

    Not in our library10.1089/ham.2015.0098

  20. 20.

    Brill S. E. Wedzicha J. A. (2014 ). Oxygen therapy in acute exacerbations of chronic obstructive pulmonary disease. Int. J. COPD 9, 1241–1252., PMID:

    Not in our library10.2147/copd.s41476

  21. 21.

    Brito J. Siqués P. León-Velarde F. De La Cruz J. J. López V. Herruzo R. (2007 ). Chronic intermittent hypoxia at high altitude exposure for over 12 years: assessment of hematological, cardiovascular, and renal effects. High Alt. Med. Biol. 8, 236–244., PMID:

    Not in our library10.1089/ham.2007.8310

  22. 22.

    Brito J. Siques P. Pena E. (2020 ). Long-term chronic intermittent hypoxia: a particular form of chronic high-altitude pulmonary hypertension. Pulm. Circ. 10, 5–12., PMID:

    Not in our library10.1177/2045894020934625

  23. 23.

    Brugniaux J. V. Hodges A. N. H. Hanly P. J. Poulin M. J. (2007 ). Cerebrovascular responses to altitude. Respir. Physiol. Neurobiol. 158, 212–223., PMID:

    Not in our library10.1016/j.resp.2007.04.008

  24. 24.

    Burke D. L. Frid M. G. Kunrath C. L. Karoor V. Anwar A. Wagner B. D.. (2009 ). Sustained hypoxia promotes the development of a pulmonary artery-specific chronic inflammatory microenvironment. Am. J. Physiol. Lung Cell. Mol. Physiol. 297, 238–250., PMID:

    Not in our library10.1152/ajplung.90591.2008

  25. 25.

    Carroll V. A. Ashcroft M. (2006 ). Role of hypoxia-inducible factor (HIF)-1α versus HIF-2α in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res. 66, 6264–6270., PMID:

    Not in our library10.1158/0008-5472.can-05-2519

  26. 26.

    Cavaillès A. Brinchault-Rabin G. Dixmier A. Goupil F. Gut-Gobert C. Marchand-Adam S.. (2013 ). Comorbidities of COPD. Eur. Respir. Rev. 22, 454–475., PMID:

    Not in our library10.1183/09059180.00008612

  27. 27.

    Celli B. R. MacNee W. Agusti A. Anzueto A. Berg B. Buist A. S.. (2004 ). Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir. J. 23, 932–946., PMID:

    Not in our library10.1183/09031936.04.00014304

  28. 28.
    Epigenetic regulation of macrophages: from homeostasis maintenance to host defense · 2019
    No notice
  29. 29.

    Clarke C. (1988 ). High altitude cerebral oedema. Int. J. Sports Med. 9, 170–174.

    Not in our library10.1055/s-2007-1024999

  30. 30.

    Coleman J. W. (2001 ). Nitric oxide in immunity and inflammation. Int. Immunopharmacol. 1, 1397–1406., PMID:

    Not in our library10.1016/s1567-5769(01)00086-8

  31. 31.

    Cook H. T. Cattell V. (1996 ). Role of nitric oxide in immune-mediated diseases. Clin. Sci. 91, 375–384., PMID:

    Not in our library10.1042/cs0910375

  32. 32.

    Couzin-Frankel J. (2020 ). The mystery of the pandemic’s ‘happy hypoxia.’. Science 368, 455–456., PMID:

    Not in our library10.1126/science.368.6490.455

  33. 33.

    Cramer T. Yamanishi Y. Clausen B. E. Förster I. Pawlinski R. Mackman N.. (2003 ). HIF-1α is essential for myeloid cell-mediated inflammation. Cell 112, 645–657., PMID:

    Not in our library10.1016/s0092-8674(03)00154-5

  34. 34.

    Crawford J. E. Amaru R. Song J. Julian C. G. Racimo F. Cheng J. Y.. (2017 ). Natural selection on genes related to cardiovascular health in high-altitude adapted andeans. Am. J. Hum. Genet. 101, 752–767., PMID:

    Not in our library10.1016/j.ajhg.2017.09.023

  35. 35.

    Cummins E. P. Berra E. Comerford K. M. Ginouves A. Fitzgerald K. T. Seeballuck F.. (2006 ). Prolyl hydroxylase-1 negatively regulates IκB kinase-β, giving insight into hypoxia-induced NFκB activity. Proc. Natl. Acad. Sci. U. S. A. 103, 18154–18159., PMID:

    Not in our library10.1073/pnas.0602235103

  36. 36.

    D’Anna F. Van Dyck L. Xiong J. Zhao H. Berrens R. V. Qian J.. (2020 ). DNA methylation repels binding of hypoxia-inducible transcription factors to maintain tumor immunotolerance. Genome Biol. 21:182., PMID:

    Not in our library10.1186/s13059-020-02087-z

  37. 37.

    Davis F. M. Gallagher K. A. (2019 ). Epigenetic mechanisms in monocytes/macrophages regulate inflammation in cardiometabolic and vascular disease. Arterioscler. Thromb. Vasc. Biol. 39, 623–634., PMID:

    Not in our library10.1161/atvbaha.118.312135

  38. 38.

    Dengler V. L. Galbraith M. D. Espinosa J. M. (2014 ). Transcriptional regulation by hypoxia inducible factors. Crit. Rev. Biochem. Mol. Biol. 49, 1–15., PMID:

    Not in our library10.3109/10409238.2013.838205

  39. 39.

    Droma Y. Hanaoka M. Basnyat B. Arjyal A. Neupane P. Pandit A.. (2006 ). Genetic contribution of the endothelial nitric oxide synthase gene to high altitude adaptation in Sherpas. High Alt. Med. Biol. 7, 209–220., PMID:

    Not in our library10.1089/ham.2006.7.209

  40. 40.

    Droma Y. Hayano T. Takabayashi Y. Koizumi T. Kubo K. Kobayashi T.. (1996 ). Endothelin-1 and interleukin-8 in high altitude pulmonary oedema. Eur. Respir. J. 9, 1947–1949., PMID:

    Not in our library10.1183/09031936.96.09091947

  41. 41.

    Dumont L. Mardirosoff C. Tramèr M. R. (2000 ). Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review. Br. Med. J. 321, 267–272., PMID:

    Not in our library10.1136/bmj.321.7256.267

  42. 42.

    Dunham-Snary K. J. Wu D. Sykes E. A. Thakrar A. Parlow L. R. G. Mewburn J. D.. (2017 ). Hypoxic pulmonary vasoconstriction: from molecular mechanisms to medicine. Chest 151, 181–192., PMID:

    Not in our library10.1016/j.chest.2016.09.001

  43. 43.

    Duplain H. Sartori C. Lepori M. Egli M. Allemann Y. Nicod P.. (2000 ). Exhaled nitric oxide in high-altitude pulmonary edema: role in the regulation of pulmonary vascular tone and evidence for a role against inflammation. Am. J. Respir. Crit. Care Med. 162, 221–224., PMID:

    Not in our library10.1164/ajrccm.162.1.9908039

  44. 44.

    Erzurum S. C. Ghosh S. Janocha A. J. Xu W. Bauer S. Bryan N. S.. (2007 ). Higher blood flow and circulating NO products offset high-altitude hypoxia among Tibetans. Proc. Natl. Acad. Sci. U. S. A. 104, 17593–17598., PMID:

    Not in our library10.1073/pnas.0707462104

  45. 45.

    Facco M. Zilli C. Siviero M. Ermolao A. Travain G. Baesso I.. (2005 ). Modulation of immune response by the acute and chronic exposure to high altitude. Med. Sci. Sports Exerc. 37, 768–774., PMID:

    Not in our library10.1249/01.mss.0000162688.54089.ce

  46. 46.

    Faquin W. C. Schneider T. J. Goldberg M. A. (1992 ). Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 79, 1987–1994.

    Not in our library

  47. 47.

    Feelisch M. (2018 ). Enhanced nitric oxide production is a universal response to hypoxic stress. Natl. Sci. Rev. 5, 532–533.

    Not in our library10.1093/nsr

  48. 48.

    Fernández A. F. Toraño E. G. Urdinguio R. G. Lana A. G. Fernández I. A. Fraga M. F. (2014 ). The epigenetic basis of adaptation and responses to environmental change: perspective on human reproduction. Adv. Exp. Med. Biol. 753, 97–117., PMID:

    Not in our library10.1007/978-1-4939-0820-2_6

  49. 49.

    Feuerecker M. Crucian B. E. Quintens R. Buchheim J. I. Salam A. P. Rybka A.. (2019 ). Immune sensitization during 1 year in the Antarctic high-altitude concordia environment. Allergy Eur. J. Allergy Clin. Immunol. 74, 64–77., PMID:

    Not in our library10.1111/all.13545

  50. 50.

    Figueroa Y. G. Chan A. K. Ibrahim R. Tang Y. Burow M. E. Alam J.. (2002 ). NF-κB plays a key role in hypoxia-inducible factor-1-regulated erythropoietin gene expression. Exp. Hematol. 30, 1419–1427., PMID:

    Not in our library10.1016/s0301-472x(02)00934-7

  51. 51.

    Foll M. Gaggiotti O. E. Daub J. T. Vatsiou A. Excoffier L. (2014 ). Widespread signals of convergent adaptation to high altitude in Asia and America. Am. J. Hum. Genet. 95, 394–407., PMID:

    Not in our library10.1016/j.ajhg.2014.09.002

  52. 52.

    Frede S. Stockmann C. Freitag P. Fandrey J. (2006 ). Bacterial lipopolysaccharide induces HIF-1 activation in human monocytes via p44/42 MAPK and NF-κB. Biochem. J. 396, 517–527., PMID:

    Not in our library10.1042/bj20051839

  53. 53.

    Gallagher S. A. Hackett P. H. (2004 ). High-altitude illness. Emerg. Med. Clin. North Am. 22, 329–355., PMID:

    Not in our library10.1016/j.emc.2004.02.001

  54. 54.

    Gertsch J. H. Corbett B. Holck P. S. Mulcahy A. Watts M. Stillwagon N. T.. (2012 ). Altitude sickness in climbers and efficacy of NSAIDs trial (ASCENT): randomized, controlled trial of ibuprofen versus placebo for prevention of altitude illness. Wilderness Environ. Med. 23, 307–315., PMID:

    Not in our library10.1016/j.wem.2012.08.001

  55. 55.

    Gertsch J. H. Lipman G. S. Holck P. S. Merritt A. Mulcahy A. Fisher R. S.. (2010 ). Prospective, double-blind, randomized, placebo-controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the headache evaluation at altitude trial (HEAT). Wilderness Environ. Med. 21, 236–243., PMID:

    Not in our library10.1016/j.wem.2010.06.009

  56. 56.

    Görlach A. Bonello S. (2008 ). The cross-talk between NF-kappaB and HIF-1: further evidence for a significant liaison. Biochem. J. 412, 17–19., PMID:

    Not in our library10.1042/bj20080920

  57. 57.

    Gozzelino R. Jeney V. Soares M. P. (2010 ). Mechanisms of cell protection by heme oxygenase-1. Annu. Rev. Pharmacol. Toxicol. 50, 323–354., PMID:

    Not in our library10.1146/annurev.pharmtox.010909.105600

  58. 58.

    Grisham M. B. Granger D. N. Lefer D. J. (1998 ). Modulation of leukocyte-endothelial interactions by reactive metabolites of oxygen and nitrogen: relevance to ischemic heart disease. Free Radic. Biol. Med. 25, 404–433., PMID:

    Not in our library10.1016/s0891-5849(98)00094-x

  59. 59.

    Groves B. M. Reeves J. T. Sutton J. R. Wagner P. D. Cymerman A. Malconian M. K.. (1987 ). Operation Everest II: elevated high-altitude pulmonary resistance unresponsive to oxygen. J. Appl. Physiol. 63, 521–530., PMID:

    Not in our library10.1152/jappl.1987.63.2.521

  60. 60.

    Gupta R. K. Soree P. Desiraju K. Agrawal A. Singh S. B. (2017 ). Subclinical pulmonary dysfunction contributes to high altitude pulmonary edema susceptibility in healthy non-mountaineers. Sci. Rep. 7:14892., PMID:

    Not in our library10.1038/s41598-017-14947-z

  61. 61.

    Haase V. H. (2013 ). Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev. 27, 41–53., PMID:

    Not in our library10.1016/j.blre.2012.12.003

  62. 62.

    Hackett P. H. (1999 ). The cerebral etiology of high-altitude cerebral edema and acute mountain sickness. Wilderness Environ. Med. 10, 97–109., PMID:

    Not in our library10.1580/1080-6032(1999)010[0097:tceoha]2.3.co;2

  63. 63.

    Hackett P. H. (2000 ). High altitude cerebral edema and acute mountain sickness: a pathophysiology update. Adv. Exp. Med. Biol. 474, 23–45.

    Not in our library10.1007/978-1-4615-4711-2_2

  64. 64.

    Hackett P. H. Roach R. C. (2004 ). High altitude cerebral edema. High Alt. Med. Biol. 5, 136–146., PMID:

    Not in our library10.1089/1527029041352054

  65. 65.

    Hackett P. H. Yarnell P. R. Weiland D. A. Reynard K. B. (2019 ). Acute and evolving MRI of high-altitude cerebral edema: microbleeds, edema, and pathophysiology. Am. J. Neuroradiol. 40, 464–469., PMID:

    Not in our library10.3174/ajnr.a5897

  66. 66.

    Hancox R. J. Poulton R. Greene J. M. Filsell S. McLachlan C. R. Rasmussen F.. (2007 ). Systemic inflammation and lung function in young adults. Thorax 62, 1064–1068., PMID:

    Not in our library10.1136/thx.2006.076877

  67. 67.

    Hartmann G. Tschöp M. Fischer R. Bidlingmaier C. Riepl R. Tschöp K.. (2000 ). High altitude increases circulating interleukin-6, interleukin-1 receptor antagonist and c-reactive protein. Cytokine 12, 246–252., PMID:

    Not in our library10.1006/cyto.1999.0533

  68. 68.

    Hayden M. S. Ghosh S. (2004 ). Signaling to NF-κB. Genes Dev. 18, 2195–2224., PMID:

    Not in our library10.1101/gad.1228704

  69. 69.

    He Y. Qi X. Ouzhuluobu Liu S. Li J. Zhang H.. (2017 ). Blunted nitric oxide regulation in Tibetans under high-altitude hypoxia. Natl. Sci. Rev. 6, 1–6.

    Not in our library10.1093/nsr/nwy037

  70. 70.

    Hirota K. (2015 ). Involvement of hypoxia-inducible factors in the dysregulation of oxygen homeostasis in sepsis. Cardiovasc. Haematol. Disord. Targets 15, 29–40., PMID:

    Not in our library10.2174/1871529x15666150108115553

  71. 71.

    Hislop A. Reid L. (1976 ). New findings in pulmonary arteries of rats with hypoxia induced pulmonary hypertension. Br. J. Exp. Pathol. 57, 542–554. PMID:

    Not in our library

  72. 72.

    Horscroft J. A. Kotwica A. O. Laner V. West J. A. Hennis P. J. Levett D. Z. H.. (2017 ). Metabolic basis to sherpa altitude adaptation. Proc. Natl. Acad. Sci. U. S. A. 114, 6382–6387., PMID:

    Not in our library10.1073/pnas.1700527114

  73. 73.

    Imagawa S. Goldberg M. A. Bunn H. F. (1990 ). Regulation of the erythropoietin gene. Adv. Exp. Med. Biol. 94, 75–85.

    Not in our library10.1182/blood.v94.6.1864

  74. 74.

    Imray C. Wright A. Subudhi A. Roach R. (2010 ). Acute mountain sickness: pathophysiology, prevention, and treatment. Prog. Cardiovasc. Dis. 52, 467–484., PMID:

    Not in our library10.1016/j.pcad.2010.02.003

  75. 75.

    Imtiyaz H. Z. Williams E. P. Hickey M. M. Patel S. A. Durham A. C. Yuan L.-J.. (2010 ). Hypoxia-inducible factor 2α regulates macrophage function in mouse models of acute and tumor inflammation. J. Clin. Invest. 120, 2699–2714., PMID:

    Not in our library10.1172/jci39506

  76. 76.

    Israël A. (2010 ). The IKK complex, a central regulator of NF-kappaB activation. Cold Spring Harb. Perspect. Biol. 2:a000158., PMID:

    Not in our library10.1101/cshperspect.a000158

  77. 77.

    Jackson A. Nanton M. R. O’Donnell H. Akue A. D. McSorley S. J. (2010 ). Innate immune activation during salmonella infection initiates extramedullary erythropoiesis and splenomegaly. J. Immunol. 185, 6198–6204., PMID:

    Not in our library10.4049/jimmunol.1001198

  78. 78.

    Jacovas V. C. Couto-Silva C. M. Nunes K. Lemes R. B. de Oliveira M. Z. Salzano F. M.. (2018 ). Selection scan reveals three new loci related to high altitude adaptation in native Andeans. Sci. Rep. 8:12733., PMID:

    Not in our library10.1038/s41598-018-31100-6

  79. 79.

    Julian C. G. Subudhi A. W. Wilson M. J. Dimmen A. C. Pecha T. Roach R. C. (2011 ). Acute mountain sickness, inflammation, and permeability: new insights from a blood biomarker study. J. Appl. Physiol. 111, 392–399., PMID:

    Not in our library10.1152/japplphysiol.00391.2011

  80. 80.

    Kaelin W. G. Ratcliffe P. J. (2008 ). Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol. Cell 30, 393–402., PMID:

    Not in our library10.1016/j.molcel.2008.04.009

  81. 81.

    Kammerer T. Faihs V. Hulde N. Stangl M. Brettner F. Rehm M.. (2020 ). Hypoxic-inflammatory responses under acute hypoxia: In vitro experiments and prospective observational expedition trial. Int. J. Mol. Sci. 21:1034., PMID:

    Not in our library10.3390/ijms21031034

  82. 82.

    Kanaan N. C. Peterson A. L. Pun M. Holck P. S. Starling J. Basyal B.. (2017 ). Prophylactic acetaminophen or ibuprofen result in equivalent acute mountain sickness incidence at high altitude: a prospective randomized trial. Wilderness Environ. Med. 28, 72–78., PMID:

    Not in our library10.1016/j.wem.2016.12.011

  83. 83.

    Keohane C. McMullin M. F. Harrison C. (2013 ). The diagnosis and management of erythrocytosis. BMJ 347:f6667., PMID:

    Not in our library10.1136/bmj.f6667

  84. 84.

    Kharitonov S. A. Barnes P. J. (2001 ). Exhaled markers of inflammation. Curr. Opin. Allergy Clin. Immunol. 1, 217–224., PMID:

    Not in our library10.1097/00130832-200106000-00004

  85. 85.

    Kidd B. L. Urban L. A. (2001 ). Mechanisms of inflammatory pain. Br. J. Anaesth. 87, 3–11., PMID:

    Not in our library10.1093/bja/87.1.3

  86. 86.

    Kim T. S. Hanak M. Trampont P. C. Braciale T. J. (2015 ). Stress-associated erythropoiesis initiation is regulated by type 1 conventional dendritic cells. J. Clin. Invest. 125, 3965–3980., PMID:

    Not in our library10.1172/jci81919

  87. 87.

    Kim I. Park J. W. (2020 ). Hypoxia-driven epigenetic regulation in cancer progression: a focus on histone methylation and its modifying enzymes. Cancer Lett. 489, 41–49., PMID:

    Not in our library10.1016/j.canlet.2020.05.025

  88. 88.

    Knauert M. Vangala S. Haslip M. Lee P. J. Ryter S. W. (2013 ). Therapeutic applications of carbon monoxide. Oxidative Med. Cell. Longev. 2013:360815., PMID:

    Not in our library10.1155/2013/360815

  89. 89.

    Kubo K. Hanaoka M. Hayano T. Miyahara T. Hachiya T. Hayasaka M.. (1998 ). Inflammatory cytokines in BAL fluid and pulmonary hemodynamics in high-altitude pulmonary edema. Respir. Physiol. 111, 301–310., PMID:

    Not in our library10.1016/s0034-5687(98)00006-1

  90. 90.

    Kubo K. Hanaoka M. Yamaguchi S. Hayano T. Hayasaka M. Koizumi T.. (1996 ). Cytokines in bronchoalveolar lavage fluid in patients with high altitude pulmonary oedema at moderate altitude in Japan. Thorax 51, 739–742., PMID:

    Not in our library10.1136/thx.51.7.739

  91. 91.

    Kvamme B. O. Gadan K. Finne-Fridell F. Niklasson L. Sundh H. Sundell K.. (2013 ). Modulation of innate immune responses in Atlantic salmon by chronic hypoxia-induced stress. Fish Shellfish Immunol. 34, 55–65., PMID:

    Not in our library10.1016/j.fsi.2012.10.006

  92. 92.

    Lakshminarayan S. Pierson D. J. (1975 ). Recurrent high altitude pulmonary edema with blunted chemosensitivity. Am. Rev. Respir. Dis. 111, 869–872., PMID:

    Not in our library10.1164/arrd.1975.111.6.869

  93. 93.

    Lawrence T. (2009 ). The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb. Perspect. Biol. 1:a001651., PMID:

    Not in our library10.1101/cshperspect.a001651

  94. 94.

    León-Velarde F. Maggiorini M. Reeves J. T. Aldashev A. Asmus I. Bernardi L.. (2005 ). Consensus statement on chronic and subacute high altitude diseases. High Alt. Med. Biol. 6, 147–157., PMID:

    Not in our library10.1089/ham.2005.6.147

  95. 95.

    Li Y. Zhang Y. Zhang Y. (2018 ). Research advances in pathogenesis and prophylactic measures of acute high altitude illness. Respir. Med. 145, 145–152., PMID:

    Not in our library10.1016/j.rmed.2018.11.004

  96. 96.

    Liao C. Sandeep Prabhu K. Paulson R. F. (2018 ). Monocyte-derived macrophages expand the murine stress erythropoietic niche during the recovery from anemia. Blood 132, 2580–2593., PMID:

    Not in our library10.1182/blood-2018-06-856831

  97. 97.

    Lipman G. S. Kanaan N. C. Holck P. S. Constance B. B. Gertsch J. H. (2012 ). Ibuprofen prevents altitude illness: a randomized controlled trial for prevention of altitude illness with nonsteroidal anti-inflammatories. Ann. Emerg. Med. 59, 484–490., PMID:

    Not in our library10.1016/j.annemergmed.2012.01.019

  98. 98.

    Liu B. Chen J. Zhang L. Gao Y. Cui J. Zhang E.. (2017 ). IL-10 dysregulation in acute mountain sickness revealed by transcriptome analysis. Front. Immunol. 8:628., PMID:

    Not in our library10.3389/fimmu.2017.00628

  99. 99.

    Luks A. M. Swenson E. R. Bärtsch P. (2017 ). Acute high-altitude sickness. Eur. Respir. Rev. 26:160096., PMID:

    Not in our library10.1183/16000617.0096-2016

  100. 100.

    Lundeberg J. Feiner J. R. Schober A. Sall J. W. Eilers H. Bickler P. E. (2018 ). Increased cytokines at high altitude: lack of effect of ibuprofen on acute mountain sickness, physiological variables, or cytokine levels. High Alt. Med. Biol. 19, 249–258., PMID:

    Not in our library10.1089/ham.2017.0144

  101. 101.

    Lüneburg N. Siques P. Brito J. Arriaza K. Pena E. Klose H.. (2016 ). Long-term chronic intermittent hypobaric hypoxia in rats causes an imbalance in the asymmetric dimethylarginine/nitric oxide pathway and ros activity: a possible synergistic mechanism for altitude pulmonary hypertension? Pulm. Med. 2016:6578578., PMID:

    Not in our library10.1155/2016/6578578

  102. 102.

    Maines M. D. (1997 ). The heme oxygenase system: a regulator of second messenger gases. Annu. Rev. Pharmacol. Toxicol. 37, 517–554., PMID:

    Not in our library10.1146/annurev.pharmtox.37.1.517

  103. 103.

    Mairbäurl H. (2018 ). Neocytolysis: how to get rid of the extra erythrocytes formed by stress erythropoiesis upon descent from high altitude. Front. Physiol. 9:345., PMID:

    Not in our library10.3389/fphys.2018.00345

  104. 104.

    Malacrida S. Giannella A. Ceolotto G. Reggiani C. Vezzoli A. Mrakic-Sposta S.. (2019 ). Transcription factors regulation in human peripheral white blood cells during hypobaric hypoxia exposure: an in-vivo experimental study. Sci. Rep. 9:9901., PMID:

    Not in our library10.1038/s41598-019-46391-6

  105. 105.

    McNicholas W. T. (2009 ). Chronic obstructive pulmonary disease and obstructive sleep apnea: overlaps in pathophysiology, systemic inflammation, and cardiovascular disease. Am. J. Respir. Crit. Care Med. 180, 692–700., PMID:

    Not in our library10.1164/rccm.200903-0347pp

  106. 106.

    Mehta S. R. Chawla A. Kashyap A. S. (2008 ). Acute mountain sickness, high altitude cerebral oedema, high altitude pulmonary oedema: the current concepts. Med. J. Armed Forces India 64, 149–153., PMID:

    Not in our library10.1016/s0377-1237(08)80062-7

  107. 107.

    Mishra K. P. Sharma N. Soree P. Gupta R. K. Ganju L. Singh S. B. (2016 ). Hypoxia-induced inflammatory chemokines in subjects with a history of high-altitude pulmonary edema. Indian J. Clin. Biochem. 31, 81–86., PMID:

    Not in our library10.1007/s12291-015-0491-3

  108. 108.

    Mitchell S. Vargas J. Hoffmann A. (2016 ). Signaling via the NFκB system. Wiley Interdiscip. Rev. Syst. Biol. Med. 8, 227–241., PMID:

    Not in our library10.1002/wsbm.1331

  109. 109.

    Moore L. G. (2017 ). Human genetic adaptation to high altitudes: current status and future prospects. Quat. Int. 461, 4–13., PMID:

    Not in our library10.1016/j.quaint.2016.09.045

  110. 110.

    Nemeth E. (2008 ). Iron regulation and erythropoiesis. Curr. Opin. Hematol. 15, 169–175., PMID:

    Not in our library10.1097/moh.0b013e3282f73335

  111. 111.

    Nemeth E. Rivera S. Gabayan V. Keller C. Taudorf S. Pedersen B. K.. (2004 ). IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 113, 1271–1276., PMID:

    Not in our library10.1172/jci200420945

  112. 112.

    Oberholzer L. Lundby C. Stauffer E. Ulliel-Roche M. Hancco I. Pichon A.. (2020 ). Reevaluation of excessive erythrocytosis in diagnosing chronic mountain sickness in men from the world’s highest city. Blood 136, 1884–1888., PMID:

    Not in our library10.1182/blood.2019004508

  113. 113.

    Oeckinghaus A. Ghosh S. (2009 ). The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb. Perspect. Biol. 1:a000034., PMID:

    Not in our library10.1101/cshperspect.a000034

  114. 114.

    Paulson R. F. Shi L. Wu D. C. (2011 ). Stress erythropoiesis: new signals and new stress progenitor cells. Curr. Opin. Hematol. 18, 139–145., PMID:

    Not in our library10.1097/moh.0b013e32834521c8

  115. 115.

    Peng Y. Yang Z. Zhang H. Cui C. Qi X. Luo X.. (2011 ). Genetic variations in tibetan populations and high-altitude adaptation at the Himalayas. Mol. Biol. Evol. 28, 1075–1081., PMID:

    Not in our library10.1093/molbev/msq290

  116. 116.

    Perkins N. D. (2006 ). Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway. Oncogene 25, 6717–6730., PMID:

    Not in our library10.1038/sj.onc.1209937

  117. 117.

    Peyssonnaux C. Cejudo-Martin P. Doedens A. Zinkernagel A. S. Johnson R. S. Nizet V. (2007 ). Cutting edge: essential role of hypoxia inducible factor-1α in development of lipopolysaccharide-induced sepsis. J. Immunol. 178, 7516–7519., PMID:

    Not in our library10.4049/jimmunol.178.12.7516

  118. 118.

    Quercioli A. Mach F. Montecucco F. (2010 ). Inflammation accelerates atherosclerotic processes in obstructive sleep apnea syndrome (OSAS). Sleep Breath. 14, 261–269., PMID:

    Not in our library10.1007/s11325-010-0338-3

  119. 119.

    Roach R. C. Hackett P. H. Oelz O. Bärtsch P. Luks A. M. MacInnis M. J.. (2018 ). The 2018 Lake Louise acute mountain sickness score. High Alt. Med. Biol. 19, 4–6., PMID:

    Not in our library10.1089/ham.2017.0164

  120. 120.

    Ryter S. W. Choi A. M. K. (2016 ). Targeting heme oxygenase-1 and carbon monoxide for therapeutic modulation of inflammation. Transl. Res. 167, 7–34., PMID:

    Not in our library10.1016/j.trsl.2015.06.011

  121. 121.
    Genetic adaptation to high altitude in the Ethiopian highlands · 2012
    No notice
  122. 122.

    Schoene R. B. Hackett P. H. Henderson W. R. Sage E. H. Chow M. Roach R. C.. (1986 ). High-altitude pulmonary edema: characteristics of lung lavage fluid. JAMA J. Am. Med. Assoc. 256, 63–69., PMID:

    Not in our library10.1001/jama.1986.03380010067027

  123. 123.

    Schoene R. B. Swenson E. R. Pizzo C. J. Hackett P. H. Roach R. C. Mills W. J.. (1988 ). The lung at high altitude: Bronchoalveolar lavage in acute mountain sickness and pulmonary edema. J. Appl. Physiol. 64, 2605–2613., PMID:

    Not in our library10.1152/jappl.1988.64.6.2605

  124. 124.

    Seldon M. P. Silva G. Pejanovic N. Larsen R. Gregoire I. P. Filipe J.. (2007 ). Heme oxygenase-1 inhibits the expression of adhesion molecules associated with endothelial cell activation via inhibition of nf-κb rela phosphorylation at serine 276. J. Immunol. 179, 7840–7851., PMID:

    Not in our library10.4049/jimmunol.179.11.7840

  125. 125.

    Semenza G. L. (2009 ). Regulation of oxygen homeostasis by hypoxia-inducible factor 1. Physiology 24, 97–106., PMID:

    Not in our library10.1152/physiol.00045.2008

  126. 126.

    Sethi S. Dikshit M. (2000 ). Modulation of polymorphonuclear leukocytes function by nitric oxide. Thromb. Res. 100, 223–247., PMID:

    Not in our library10.1016/s0049-3848(00)00320-0

  127. 127.

    Shaaban R. Kony S. Driss F. Leynaert B. Soussan D. Pin I.. (2006 ). Change in C-reactive protein levels and FEV1 decline: a longitudinal population-based study. Respir. Med. 100, 2112–2120., PMID:

    Not in our library10.1016/j.rmed.2006.03.027

  128. 128.

    Sharma J. N. Al-Omran A. Parvathy S. S. (2007 ). Role of nitric oxide in inflammatory diseases. Inflammopharmacology 15, 252–259., PMID:

    Not in our library10.1007/s10787-007-0013-x

  129. 129.

    Simonson T. S. Yang Y. Huff C. D. Yun H. Qin G. Witherspoon D. J.. (2010 ). Genetic evidence for high-altitude adaptation in Tibet. Science 329, 72–75., PMID:

    Not in our library10.1126/science.1189406

  130. 130.

    Siques P. López De Pablo Á. L. Brito J. Arribas S. M. Flores K. Arriaza K.. (2014 ). Nitric oxide and superoxide anion balance in rats exposed to chronic and long term intermittent hypoxia. Biomed. Res. Int. 2014:610474., PMID:

    Not in our library10.1155/2014/610474

  131. 131.
    Systemic pro-inflammatory response facilitates the development of cerebral edema during short hypoxia · 2016
    No notice
  132. 132.

    Stenmark K. R. Yeager M. E. El Kasmi K. C. Nozik-Grayck E. Gerasimovskaya E. V. Li M.. (2013 ). The adventitia: essential regulator of vascular wall structure and function. Annu. Rev. Physiol. 75, 23–47., PMID:

    Not in our library10.1146/annurev-physiol-030212-183802

  133. 133.

    Swenson E. R. (2013 ). Hypoxic pulmonary vasoconstriction. High Alt. Med. Biol. 14, 101–110., PMID:

    Not in our library10.1089/ham.2013.1010

  134. 134.

    Swenson E. R. (2020 ). Early hours in the development of high-altitude pulmonary edema: time course and mechanisms. J. Appl. Physiol. 128, 1539–1546., PMID:

    Not in our library10.1152/japplphysiol.00824.2019

  135. 135.

    Swenson E. R. Maggiorini M. Mongovin S. Simon R. Gibbs J. Greve I.. (2002 ). Pathogenesis of high-altitude pulmonary edema: inflammation is not an etiologic factor. J. Am. Med. Assoc. 287, 2228–2235., PMID:

    Not in our library10.1001/jama.287.17.2228

  136. 136.

    Sydykov A. Mamazhakypov A. Maripov A. Kosanovic D. Weissmann N. Ghofrani H. A.. (2021 ). Pulmonary hypertension in acute and chronic high altitude maladaptation disorders. Int. J. Environ. Res. Public Health 18:1692., PMID:

    Not in our library10.3390/ijerph18041692

  137. 137.

    Talbot N. P. Balanos G. M. Dorrington K. L. Robbins P. A. (2005 ). Two temporal components within the human pulmonary vascular response to ∼2 h of isocapnic hypoxia. J. Appl. Physiol. 98, 1125–1139., PMID:

    Not in our library10.1152/japplphysiol.00903.2004

  138. 138.

    Tasali E. Ip M. S. M. (2008 ). Obstructive sleep apnea and metabolic syndrome: alterations in glucose metabolism and inflammation. Proc. Am. Thorac. Soc. 5, 207–217., PMID:

    Not in our library10.1513/pats.200708-139mg

  139. 139.

    Taylor C. T. (2008 ). Interdependent roles for hypoxia inducible factor and nuclear factor-κB in hypoxic inflammation. J. Physiol. 586, 4055–4059., PMID:

    Not in our library10.1113/jphysiol.2008.157669

  140. 140.

    Taylor C. T. Colgan S. P. (2017 ). Regulation of immunity and inflammation by hypoxia in immunological niches. Nat. Rev. Immunol. 17, 774–785., PMID:

    Not in our library10.1038/nri.2017.103

  141. 141.

    Taylor C. T. Moncada S. (2010 ). Nitric oxide, cytochrome c oxidase, and the cellular response to hypoxia. Arterioscler. Thromb. Vasc. Biol. 30, 643–647., PMID:

    Not in our library10.1161/atvbaha.108.181628

  142. 142.

    Thienpont B. Steinbacher J. Zhao H. D’Anna F. Kuchnio A. Ploumakis A.. (2016 ). Tumour hypoxia causes DNA hypermethylation by reducing TET activity. Nature 537, 63–68., PMID:

    Not in our library10.1038/nature19081

  143. 143.

    Tie R. Li H. Cai S. Liang Z. Shan W. Wang B.. (2019 ). Interleukin-6 signaling regulates hematopoietic stem cell emergence. Exp. Mol. Med. 51, 1–12., PMID:

    Not in our library10.1038/s12276-019-0320-5

  144. 144.

    Tift M. S. Alves de Souza R. W. Weber J. Heinrich E. C. Villafuerte F. C. Malhotra A.. (2020 ). Adaptive potential of the heme oxygenase/carbon monoxide pathway during hypoxia. Front. Physiol. 11:886., PMID:

    Not in our library10.3389/fphys.2020.00886

  145. 145.

    Tobin M. J. Laghi F. Jubran A. (2020 ). Why COVID-19 silent hypoxemia is baffling to physicians. Am. J. Respir. Crit. Care Med. 202, 356–360., PMID:

    Not in our library10.1164/rccm.202006-2157cp

  146. 146.

    Van Uden P. Kenneth N. S. Rocha S. (2008 ). Regulation of hypoxia-inducible factor-1α by NF-κB. Biochem. J. 412, 477–484., PMID:

    Not in our library10.1042/bj20080476

  147. 147.

    Varatharaj A. Galea I. (2017 ). The blood-brain barrier in systemic inflammation. Brain Behav. Immun. 60, 1–12., PMID:

    Not in our library10.1016/j.bbi.2016.03.010

  148. 148.

    Villafuerte F. C. Macarlupú J. L. Anza-Ramírez C. Corrales-Melgar D. Vizcardo-Galindo G. Corante N.. (2014 ). Decreased plasma soluble erythropoietin receptor in high-altitude excessive erythrocytosis and Chronic Mountain sickness. J. Appl. Physiol. 117, 1356–1362., PMID:

    Not in our library10.1152/japplphysiol.00619.2014

  149. 149.

    Walmsley S. Harris A. Thompson A. A. R. Whyte M. K. B. (2014 ). HIF-mediated innate immune responses: cell signaling and therapeutic implications. Hypoxia 2, 47–58., PMID:

    Not in our library10.2147/hp.s50269

  150. 150.

    Walmsley S. R. Print C. Farahi N. Peyssonnaux C. Johnson R. S. Cramer T.. (2005 ). Hypoxia-induced neutrophil survival is mediated by HIF-1α-dependent NF-κB activity. J. Exp. Med. 201, 105–115., PMID:

    Not in our library10.1084/jem.20040624

  151. 151.

    Wang C. Jiang H. Duan J. Chen J. Wang Q. Liu X.. (2018 ). Exploration of acute phase proteins and inflammatory cytokines in early stage diagnosis of acute mountain sickness. High Alt. Med. Biol. 19, 170–177., PMID:

    Not in our library10.1089/ham.2017.0126

  152. 152.

    Watts E. R. Walmsley S. R. (2019 ). Inflammation and hypoxia: HIF and PHD isoform selectivity. Trends Mol. Med. 25, 33–46., PMID:

    Not in our library10.1016/j.molmed.2018.10.006

  153. 153.

    Weiss G. Ganz T. Goodnough L. T. (2019 ). Anemia of inflammation. Blood 133, 40–50., PMID:

    Not in our library10.1182/blood-2018-06-856500

  154. 154.

    Wenger R. H. Stiehl D. P. Camenisch G. (2005 ). Integration of oxygen signaling at the consensus HRE. Sci. STKE 2005:re12., PMID:

    Not in our library10.1126/stke.3062005re12

  155. 155.

    West J. B. (2004 ). The physiologic basis of high-altitude diseases. Ann. Intern. Med. 141:789., PMID:

    Not in our library10.7326/0003-4819-141-10-200411160-00010

  156. 156.

    Wilkins M. R. Ghofrani H. A. Weissmann N. Aldashev A. Zhao L. (2015 ). Pathophysiology and treatment of high-altitude pulmonary vascular disease. Circulation 131, 582–590., PMID:

    Not in our library10.1161/circulationaha.114.006977

  157. 157.

    Xie J. Covassin N. Fan Z. Singh P. Gao W. Li G.. (2020 ). Association between hypoxemia and mortality in patients with COVID-19. Mayo Clin. Proc. 95, 1138–1147., PMID:

    Not in our library10.1016/j.mayocp.2020.04.006

  158. 158.

    Yang J. Jin Z. B. Chen J. Huang X. F. Li X. M. Liang Y. B.. (2017 ). Genetic signatures of high-altitude adaptation in Tibetans. Proc. Natl. Acad. Sci. U. S. A. 114, 4189–4194., PMID:

    Not in our library10.1073/pnas.1617042114

  159. 159.

    Yang D. Peng Y. Ouzhuluobu B. Cui C. Bianba Wang L.. (2016 ). HMOX2 functions as a modifier gene for high-altitude adaptation in Tibetans. Hum. Mutat. 37, 216–223., PMID:

    Not in our library10.1002/humu.22935

  160. 160.

    Zaritsky J. Young B. Wang H. J. Westerman M. Olbina G. Nemeth E.. (2009 ). Hepcidin—A potential novel biomarker for iron status in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 4, 1051–1056., PMID:

    Not in our library10.2215/cjn.05931108

  161. 161.

    Zhang C. Lu Y. Feng Q. Wang X. Lou H. Liu J.. (2017 ). Differentiated demographic histories and local adaptations between Sherpas and Tibetans. Genome Biol. 18:115., PMID:

    Not in our library10.1186/s13059-017-1242-y

  162. 162.

    Zheng C. R. Chen G. Z. Yu J. Qin J. Song P. Bian S. Z.. (2014 ). Inhaled budesonide and oral dexamethasone prevent acute mountain sickness. Am. J. Med. 127, 1001–1009.e2., PMID:

    Not in our library10.1016/j.amjmed.2014.04.012

  163. 163.

    Zhou Y. Huang X. Zhao T. Qiao M. Zhao X. Zhao M.. (2017 ). Hypoxia augments LPS-induced inflammation and triggers high altitude cerebral edema in mice. Brain Behav. Immun. 64, 266–275., PMID:

    Not in our library10.1016/j.bbi.2017.04.013

  164. 164.

    Zhou J. Schmid T. Brüne B. (2003 ). Tumor necrosis factor-α causes accumulation of a ubiquitinated form of hypoxia inducible factor-1α through a nuclear factor-κB-dependent pathway. Mol. Biol. Cell 14, 2216–2225., PMID:

    Not in our library10.1091/mbc.e02-09-0598

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.